Democratic People's Republic of Korea

Population 2018 26 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>131 (114–149)</td>
<td>513 (446–584)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.22 (0.12–0.36)</td>
<td>0.87 (0.47–1.4)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>5.2 (2.5–8.8)</td>
<td>20 (10–34)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>20 (14–27)</td>
<td>80 (56–107)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.088 (0.035–0.11)</td>
<td>0.27 (0.14–0.44)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases 2.2%
Previously treated cases 16% (9.1–25)

TB case notifications, 2018
Total new and relapse 89 939
  - % tested with rapid diagnostics at time of diagnosis
    - % with known HIV status 0%
    - % pulmonary 80%
    - % bacteriologically confirmed** 50%
    - % children aged 0-14 years 5%
    - % women 34%
    - % men 61%
Total cases notified 95 245

Universal health coverage and social protection
TB treatment coverage (notified/estimated incidence), 2018 69% (60–79)
TB patients facing catastrophic total costs
TB case fatality ratio (estimated mortality/estimated incidence), 2018 16% (11–21)

TB/HIV care in new and relapse TB patients, 2018
Patients with known HIV status who are HIV-positive 0
  - on antiretroviral therapy 0

Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance**
  - New cases
    - Previously treated cases 20%
Laboratory-confirmed cases* MDR/RR-TB: 1 782, XDR-TB: 0
Patients started on treatment** MDR/RR-TB: 1 487, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs 0

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>New and relapse cases registered in 2017</th>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>83%</td>
<td>100 553</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Previously treated cases, excluding relapse, registered in 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDR/RR-TB cases started on second-line treatment in 2016</td>
</tr>
<tr>
<td>% HIV-positive people (newly enrolled in care) on preventive treatment</td>
</tr>
<tr>
<td>% of children (aged &lt; 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 100%</td>
</tr>
</tbody>
</table>

TB financing, 2019
National TB budget (US$ millions) 50
Funding source: 12% domestic, 14% international, 75% unfunded

Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-10-18 Data: www.who.int/tb/data